Elanco Animal Health Incorporated Common Stock
Here’s whether Elanco Animal Health Incorporated Common Stock (ELAN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 55 — healthy momentum range; strong 1-year return of +192.3%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.87% over 10 days); declining volume on rally — weak conviction (0.78x 30d avg). Currently 14.6% off its 52-week high. Score: +1/7.
ELAN is holding above its long-term 200-day MA ($21.11) but has slipped below the 50-day MA ($24.36), pointing to short-term weakness in an otherwise intact trend. An RSI of 54.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +192.3% compares to +35.1% for SPY (beat the market by 157.3%).